At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Patients With Non-Hodgkin's Lymphoma
In Brief
A clinical study evaluating Aprepitant, Cyclophosphamide, and 5 other interventions for Lymphoma. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn the effect of combining aprepitant with CHOP or R-CHOP in patients with Non-Hodgkin's Lymphoma (NHL) that is either newly diagnosed or has come back. Researchers also want to see if aprepitant can help to prevent nausea and/or vomiting that may be caused by chemotherapy treatment with CHOP or R-CHOP, in these patients. CHOP consists of four drugs - Cyclophosphamide (also called Cytoxan/Neosar), Doxorubicin (or Adriamycin), Vincristine (Oncovin) and Prednisolone while R-CHOP includes Rituximab and CHOP.
Study Details
Timeline
Interventions
125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
750 mg/m\^2 By Vein On Day 1
25 mg/m\^2 By Vein Over 48 Hours On Days 1-2
2 mg By Vein On Day 1
100 mg PO for 5 Days
375 mg/m\^2 By Vein On Day 1.
8 mg daily for 2 days